Haug Alexander R
Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria -
Q J Nucl Med Mol Imaging. 2017 Sep;61(3):292-300. doi: 10.23736/S1824-4785.17.02994-6.
The use of positron-emission tomography (PET) with fluorodeoxyglucose (FDG), 11C-acetate and radio-labelled choline such as 11C-choline or 18F-fluorocholine in the diagnosis of hepatocellular carcinoma (HCC), for risk stratification or therapy monitoring has emerged. This review aims to summarize the published results dealing with this issue.
PubMed database was searched until February 2017. Sensitivities, specificities, progression-free survival (PFS), survival and hazard ratios (HR) are reported.
Seventy-one studies were included. Most studies are dealing with the diagnostic value of FDG PET (N.=21), 11C-acetate PET (N.=11), and choline PET (N.=8). The results indicate a homogenously higher sensitivity for 11C-acetate and choline PET as compared to FDG PET in the diagnosis of primary or recurrent HCC. This is particularly true for well differentiated HCC, which tend to have higher uptake of 11C-acetate and radio-labelled choline. Contrary, poorly differentiated HCC are more often FDG-positive than well differentiated HCC. Sixteen studies are evaluating the prognostic value of FDG PET for surgery or liver transplantation. The studies found a significant worse prognosis in terms of time to recurrence, PFS, and survival in FDG-positive HCC as compared to FDG-negative ones. Sixteen studies are reporting about the prognostic value of FDG PET and one about 18F-fluoroethylcholine PET for palliative treatment. Most of these studies indicate a significant shorter PFS and survival in FDG-positive HCC for various treatments.
Whereas FDG PET has only a limited role in the diagnosis of HCC, it provides valuable prognostic information for liver surgery, transplantation and palliative treatment. 11C-acetate and choline PET have a higher sensitivity in the diagnosis of HCC.
正电子发射断层扫描(PET)联合氟脱氧葡萄糖(FDG)、11C-乙酸盐以及放射性标记胆碱(如11C-胆碱或18F-氟胆碱)在肝细胞癌(HCC)诊断、风险分层或治疗监测中的应用已逐渐兴起。本综述旨在总结已发表的关于该问题的研究结果。
检索PubMed数据库至2017年2月。报告了敏感性、特异性、无进展生存期(PFS)、生存率和风险比(HR)。
纳入71项研究。大多数研究涉及FDG PET(n = 21)、11C-乙酸盐PET(n = 11)和胆碱PET(n = 8)的诊断价值。结果表明,在原发性或复发性HCC诊断中,与FDG PET相比,11C-乙酸盐和胆碱PET的敏感性普遍更高。对于高分化HCC尤其如此,其往往对11C-乙酸盐和放射性标记胆碱摄取更高。相反,低分化HCC比高分化HCC更常为FDG阳性。16项研究评估了FDG PET对手术或肝移植的预后价值。研究发现,与FDG阴性的HCC相比,FDG阳性的HCC在复发时间、PFS和生存率方面预后明显更差。16项研究报告了FDG PET的预后价值,1项研究报告了18F-氟乙基胆碱PET对姑息治疗的预后价值。这些研究中的大多数表明,对于各种治疗,FDG阳性的HCC的PFS和生存期明显更短。
虽然FDG PET在HCC诊断中的作用有限,但它为肝手术、移植和姑息治疗提供了有价值的预后信息。11C-乙酸盐和胆碱PET在HCC诊断中具有更高的敏感性。